EGFR and non-small cell lung carcinoma: The TIMELY trial was initiated in 2013 and designed to investigate the safety and efficacy of afatinib in NSCLC patients with comorbidities considered unsuitable for chemotherapy and who had suspected or confirmed EGFR mutation.